KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Operating Expenses (2019 - 2025)

Aurinia Pharmaceuticals' Operating Expenses history spans 7 years, with the latest figure at $43.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 28.7% year-over-year to $43.9 million; the TTM value through Dec 2025 reached $178.1 million, down 25.72%, while the annual FY2025 figure was $178.1 million, 25.72% down from the prior year.
  • Operating Expenses reached $43.9 million in Q4 2025 per AUPH's latest filing, roughly flat from $43.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $74.8 million in Q4 2023 to a low of $40.6 million in Q1 2025.
  • Average Operating Expenses over 5 years is $57.9 million, with a median of $58.2 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 99.89% in 2021, then plummeted 36.09% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $56.1 million in 2021, then increased by 0.76% to $56.5 million in 2022, then skyrocketed by 32.25% to $74.8 million in 2023, then fell by 17.7% to $61.5 million in 2024, then fell by 28.7% to $43.9 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Operating Expenses are $43.9 million (Q4 2025), $43.7 million (Q3 2025), and $49.9 million (Q2 2025).